Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT) Stock Overview

Explore Adaptive Biotechnologies Corporation’s financial performance, market position, analyst ratings, and future outlook.

ADPT●NASDAQ
HealthcareBiotechnology
$22.27
$0.04(0.18%)
U.S. Market opens in 63h 26m

Adaptive Biotechnologies Corporation (ADPT)

Meyka AI Score

Z

Key Financials

Market Cap3.6B
P/E Ratio-68.17
EPS (TTM)$-0.54
ROE-0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$23.90
3 Months$21.55
1 Year Target$24.16

ADPT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Adaptive Biotechnologies Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ADPT on the NASDAQ shows an RSI of 57.70, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $24.16 for the NASDAQ listing.

Key metrics behind Adaptive Biotechnologies Corporation's NASDAQ-traded stock include a P/E ratio of -68.17 and a market capitalization of 3.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADPT on the NASDAQ.

Price Performance (NASDAQ: ADPT)

1-Day Change
-0.18%
5-Day Change
3.92%
1-Month Change
15.15%
3-Month Change
57.50%
6-Month Change
20.05%
Year-to-Date (YTD) Change
37.13%
1-Year Change
108.91%
3-Year Change
185.51%
5-Year Change
-39.52%
All-Time (Max) Change
-44.74%

Contact Information

https://www.adaptivebiotech.com
206 659 0067
1165 Eastlake Avenue East, Seattle, WA, 98109

Company Facts

6,240 Employees
IPO DateJun 27, 2019
CountryUS
Actively Trading

Frequently Asked Questions